Paper Review Records
全部论文审稿周期
29 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期;保留 PDF/DOI/网页源链接
151
天
Artificial intelligence aids multi-omics data integration in cancer drug discovery and development: from targets to drug synergy
作者
Yi-le Yang; Qi-yue Wang; Yong-qiang Zhou; Xin-ying Zhang; Zhuo-bin Chen; Yong Liu; Yao-hua Hu; Jun-wen Wang; Jing Qin展开收起
作者单位
1. School of Pharmaceutical Sciences, Sun Yat-sen University Shenzhen Campus, Shenzhen, China; 2. School of Pharmacy, Zhejiang University, Hangzhou, China; 3. School of Artificial Intelligence, Guangxi Minzu University, Nanning, China; 4. School of Mathematical Sciences, Shenzhen University, Shenzhen, China; 5. Division of Applied Oral Sciences & Community Dental Care, Faculty of Dentistry, The University of Hong Kong, Hong Kong SAR, China展开收起
166
天
IRAK4 inhibitor DW18134 ameliorates diffuse large B-cell lymphoma in combination with ibrutinib and overcomes acquired resistance to ibrutinib
作者
Yi Ning; Yu Zhou; Qi Zhang; Zhi-wei Chen; Yu-qing Huang; Qi Zhang; Yun Chen; Wen-hao Shi; Qiu-pei Liu; Ya-ping Xue; Tao Zhang; Jian Ding; Wen-hu Duan; Hua Xie展开收起
作者单位
1. Division of Antitumor Pharmacology & State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China; 2. University of Chinese Academy of Sciences, Beijing, China; 3. Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan, China; 4. Small-Molecule Drug Research Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China; 5. Department of Chemical and Environmental Engineering, Science and Engineering Building, The University of Nottingham Ningbo China, Ningbo, China展开收起
142
天
Structure-based virtual screening with AlphaFold identifies CLIP1-LTK inhibitors
作者
Wang-lin Qu; Xu-jun Zhang; Gao-ang Wang; Wei-xin Tian; Kang Chen; Yuan-yi Ye; Shi-cheng Chen; Ru-bi Hu; Yi-fei Liu; Chao Shen; Dan Li; Yu Kang; Sheng Tian; Peng Teng; Ting-jun Hou; Pei-chen Pan展开收起
作者单位
1. College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China; 2. Department of Clinical Pharmacy, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China; 3. College of Pharmaceutical Sciences, Soochow University, Suzhou, China; 4. Zhejiang Key Laboratory of Intelligent Drug Discovery and Development, Jinhua Institute of Zhejiang University, Jinhua, China展开收起
103
天
Hesperetin ameliorates APAP-induced liver injury by activating a PKC–TFEB axis
作者
Shu-jun Chen; Yi-xin Chen; Yu-jie Zhao; Jing-min Zeng; Shi-yun Tan; Hao Wang; Li-rong Wang; Xiao-juan Chao; Shao-gui Wang展开收起
作者单位
1. State Key Laboratory of Traditional Chinese Medicine Syndrome, Chinese Medicine Guangdong Laboratory (Hengqin Laboratory), International Institute for Translational Chinese Medicine, School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, China; 2. Key Laboratory of Chinese Medicinal Resource from Lingnan (Guangzhou University of Chinese Medicine), Ministry of Education, Guangzhou, China; 3. Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, China; 4. Department of Gastroenterology and Hepatology, Institute of Precision Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China; 5. Dongguan Institute of Guangzhou University of Chinese Medicine, Dongguan, China展开收起
1
天
Anticancer drug discovery: Embracing the next wave of innovation
作者
Min Huang; Mei-yu Geng; Jian Ding展开收起
作者单位
1. State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China; 2. University of Chinese Academy of Sciences, Beijing, China展开收起
60
天
Inhibition of histone deacetylase 3 alleviates lithocholic acid-induced intrahepatic cholestasis by enhancing expression of bile acid and lipid homeostasis-related genes
作者
Jing-shu Li; Xiao-wen Jiang; Pei-bin Chen; Xuan Li; Xiao Yang; Shi-cheng Fan; Yue Gao; Jian-hong Fang; Feng Qiu; Hui-chang Bi展开收起
作者单位
1. Department of Laboratory Medicine, The Seventh Affiliated Hospital, Southern Medical University, Foshan, China; 2. State Key Laboratory of Multi-organ Injury Prevention and Treatment, Guangdong Provincial Key Laboratory of New Drug Screening & Guangdong-Hong Kong-Macao Joint Laboratory for New Drug Screening, Key Laboratory of Mental Health of the Ministry of Education, Guangdong Basic Research Center of Excellence for Integrated Traditional and Western Medicine for Qingzhi Diseases, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China展开收起
FAQ
ACTA PHARMACOLOGICA SINICA审稿要多久?
截至2026-11-18,CrushSCI 收录了 ACTA PHARMACOLOGICA SINICA 的 29 篇完整审稿记录。最快一篇从收稿到录用用了 1 天(Anticancer drug discovery: Embracing the next wave of innovation,2026-09-29 收稿,2026-09-30 录用),最慢一篇用了 235 天;平均 131 天,中位数 125 天。最快这篇的日期间隔异常短,建议点开原文核对。
Expert Matching · Case Demo
把投稿要求,转成可验证的期刊方案
说清专业、时限和作者背景,CrushSCI 结合真实审稿样本,给出拟题方向、期刊初筛与周期判断。
